Welcome to our dedicated page for aTYR PHARMA SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma Inc. reported an insider equity award to its President and CEO, Sanjay Shukla. On January 9, 2026, he was granted an employee stock option for 1,500,000 shares of common stock at an exercise price of $0.7127 per share. The Form 4 shows the transaction as acquired and held directly, with 1,500,000 derivative securities beneficially owned after the grant.
The option will vest in 36 equal monthly installments beginning February 9, 2026, and is expected to be fully exercisable by January 9, 2029. The award agreement also provides for accelerated vesting if Dr. Shukla is terminated without cause in connection with a change of control of the company.
aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported a grant of 412,500 Employee Stock Options on January 9, 2026. The options have an exercise price of $0.7127 per share and were granted at $0 cost, increasing her derivative holdings to 412,500 options.
According to the filing, these options vest in 36 equal monthly installments beginning February 9, 2026 and are scheduled to be fully exercisable on January 9, 2029, with potential accelerated vesting if she is terminated without cause following a change of control. After this grant, she beneficially owns 35,104 shares of common stock, including shares acquired through the company’s 2015 Employee Purchase Plan.
aTyr Pharma Inc.'s General Counsel, Nancy Denyes, reported a new equity award and current holdings. On January 9, 2026, she was granted 412,500 Employee Stock Options with an exercise price of $0.7127 per share. These options vest in 36 equal monthly installments beginning February 9, 2026, becoming fully exercisable on January 9, 2029, and are subject to accelerated vesting if she is terminated without cause in connection with a change of control of the company.
Following this grant, she beneficially owns 31,555 shares of aTyr Pharma common stock directly, which include 2,500 shares acquired on May 15, 2025 and 2,500 shares acquired on November 14, 2025 under the company’s 2015 Employee Purchase Plan.
aTyr Pharma (ATYR) reported Q3 2025 results showing continued investment in its pipeline and a larger loss as it advances efzofitimod. License and collaboration revenue was $190 thousand. Research and development expense rose to $22.1 million, and general and administrative expense was $4.8 million, leading to a net loss of $25.7 million (basic and diluted net loss per share $0.26).
Cash, cash equivalents and available-for-sale investments totaled $92.9 million as of September 30, 2025. Year-to-date, the company raised $66.4 million via its Jefferies at‑the‑market program, selling 13,887,177 shares at a weighted‑average price of $4.94. Operating cash use for the first nine months was $49.8 million. Shares outstanding were 97,986,634 as of September 30, 2025.
The company announced that the Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, though nominal improvements were observed on certain symptom measures, and efzofitimod was generally well‑tolerated. Management plans to meet the FDA in the first quarter of 2026 to discuss a path forward. Two putative securities class action complaints were filed in October 2025; no liability has been recorded.
aTyr Pharma (ATYR) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to an Item 2.02 Form 8-K. The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL data.
aTYR Pharma (ATYR) director Paul Schimmel reported purchases totaling 1,000,000 common shares across 10/08/2025 and 10/09/2025 at weighted average prices of $0.898 and $0.9414 respectively. After these transactions the reporting person beneficially owned 1,413,023 shares indirectly through trusts and a prototype PSP vehicle. The filings note share purchase price ranges from $0.8536 to $0.95 for the first lot and $0.93 to $0.95 for the second, and identify ownership via the Paul Schimmel Prototype PSP and the Schimmel Revocable Trust.
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
aTYR Pharma reported results from a 268-patient global Phase 3 study in pulmonary sarcoidosis comparing efzofitimod 3.0 mg/kg and 5.0 mg/kg versus placebo over 48 weeks with a protocol-guided steroid taper. The primary steroid-reduction endpoint showed mean daily oral corticosteroid (OCS) doses of 2.79 mg for 5.0 mg/kg efzofitimod versus 3.52 mg for placebo (p=0.3313), which was not statistically significant. Secondary measures showed a statistically significant improvement in KSQ-Lung score for 5.0 mg/kg (change 10.36 vs 6.19; p=0.0479) and a higher rate of complete steroid withdrawal with KSQ-Lung improvement (29.5% vs 14.4%; p=0.0199). Change in FVC was similar between groups (−1.81 vs −2.11; p=0.7875). Treatment was generally well tolerated at both doses.